ability to show differences between interventions. The project investigated the feasibility of deriving relative and absolute utility values from the RGHQoL. METHODS: A discrete choice conjoint analysis (CA) task (for eliciting relative utility) and time trade off (TTO) exercise (absolute utility) were designed using QoL states generated from a subset of six RGHQoL items. RGH patients completed tasks via interview. CA data were analysed using the random effects probit model. For TTO, a random effects tobit regression was employed to estimate absolute utility values for combinations of attribute levels not presented in the valuation exercise. RESULTS: One hundred and ninety-two (92.8%) of these. Respondents were asked to indicate how many years spent in specific QoL states would be equivalent to 10 years with perfect QoL. Many respondents struggled to grasp the concept of TTO and provided inconsistent responses as a consequence. In contrast, the degree of completeness and consistency with the discrete choice CA exercise was high. Further research should explore the potential use of CA in developing utilities that possess qualities such that these can be used directly within a QALY framework.

INFECTION—Healthcare Policy

FACTORS INFLUENCING INAPPROPRIATE ANTIBIOTIC PRESCRIBING FOR CHILDREN WITH ACUTE BRONCHITIS IN AMBULATORY CARE SETTING

Koompalum D, Martin BC

University of Georgia, Athens, GA, USA

OBJECTIVES: Although the antibiotic prescribing rate for pediatric respiratory tract infections in the ambulatory care setting decreased significantly from 1989 to 2000, the rate for acute bronchitis remains high. This study sought to identify factors associated with antibiotic prescribing for acute bronchitis and to confirm changes in antibiotic prescribing rates from 1996 to 1999 for URIs, colds, and bronchitis. METHODS: A retrospective analysis of antibiotic use in U.S. office-based settings was conducted using the 1996 and 1999 National Ambulatory Medical Care Survey (NAMCS). Children <18 years diagnosed with acute bronchitis (bronchitis, ICD-9-CM;466**,490**), nasopharyngitis (common colds,ICD-9-CM;460**,466**,490**), acute upper respiratory tract infections (URIs,ICD-9-CM;465**) were selected. We excluded persons that were diagnosed with any condition for which an antibiotic may be appropriate. Antibiotic use was determined by searching all prescription codes for antimicrobial agents (NDC;0346–0358). Logistic regression was used to identify significant patient, health system, and physician characteristics associated with antibiotic prescribing. RESULTS: Over the 1996 to 1999 period, antibiotic prescribing decreased from 73% to 17% and 37% to 20% for colds and URI visits. In 1999, there were 2.2 million pediatric visits for acute bronchitis and 79.1% received an antibiotic which was relatively unchanged from the rated of 86% observed in 1996. Antibiotic classes prescribed for bronchitis included
Erythomycins/lincosamin/macrolides (49%), Penicillins (39%), Cephalosporin (9%) and Sulfonamides/Trimethoprim (3%). Out of 6 factors explored, only pediatricians were more likely to prescribe antibiotics for acute bronchitis than non-pediatricians (OR = 12.78; 95% CI, 1.42–115.19). CONCLUSIONS: Our study confirms the dramatic decrease in potentially inappropriate antibiotic prescribing for children diagnosed with common colds and URI. The rate of potentially inappropriate antibiotic prescribing remained high (79%) for children diagnosed with bronchitis with the highest rates observed for children seeking care from a pediatrician. More than half of antibiotic classes prescribed for bronchitis were considered to be ineffective for underlining pathogens in cases of bacterial bronchitis complications.

**PIN34**

**INITIAL ANTIVIRAL TREATMENT OF CHRONIC HEPATITIS C: A GERMAN HEALTH TECHNOLOGY ASSESSMENT AND DECISION ANALYSIS**

Siebert U1, Sprczynski G2, Wong JB3

1Harvard School of Public Health and University of Munich, Boston, MA, USA; 2University of Munich, Munich, Germany; 3Tufts University School of Medicine, Boston, MA, USA

OBJECTIVES: The objective of this health technology assessment (HTA) commissioned by the German Agency for HTA/ German Federal Ministry of Health was to establish an interdisciplinary expert network, to systematically review the evidence on effectiveness and cost-effectiveness of initial antiviral combination therapy for chronic hepatitis C (CHC) and to apply these data in the context of the German health care system. METHODS: A systematic literature review was conducted and study quality/transferability to the German context were assessed using standard instruments of the German Agency for HTA. A decision-analytic Markov model was developed including pooled short-term outcomes (survival and virological response [SVR] and respective pooled relative risks) from a recently published Cochrane review, single RCTs, utilities from a large German general population sample, and German cost data. The model was used to determine long-term morbidity, life expectancy, and lifetime costs of different treatment strategies using the societal perspective. One- and multi-way sensitivity analyses were performed. RESULTS: International clinical studies indicate that combination therapy with pegylated interferon and ribavirin (PCOM) achieves highest SVR (54–61%), followed by standard combination therapy with interferon and ribavirin (SCOM) with 37–54%, and interferon monotherapy (MONO) with 11–21%. Based on international cost-effectiveness studies, SCOM is “cost-effective” compared to MONO. Our decision analysis confirmed these findings for the German health care context. No published articles were available for assessing the cost-effectiveness of PCOM. Based on our decision analysis, PCOM dominated SCOM, and its discounted incremental cost-effectiveness ratio compared to MONO was €8,200 per quality-adjusted life year. These results were robust in sensitivity analyses. CONCLUSIONS: This HTA suggests that initial combination therapy should prolong life, improve quality-adjusted life expectancy, and be cost-effective in patients with chronic hepatitis C. The combination of pegylated interferon and ribavirin is currently the most effective and efficient antiviral treatment for CHC.

**PIN35**

**VARICELLA VACCINATION OF PRE-SCHOOL CHILDREN: DETERMINING OPTIMAL COVERAGE LEVELS**

Klose T1, Banz K2, Goertz A1, Wagenpfeil S3, Neiss A3, Wutzler P1

1GlaxoSmithKline, Munich, Germany; 2Outcomes International, Basel, Switzerland; 3Institute for Medical Statistics and Epidemiology at Technical University Munich, Munich, Germany; 4University of Jena, Jena, Germany

OBJECTIVES: High coverage is crucial for the success of vaccination strategies. We investigate the effect of different coverage levels of varicella vaccination in Germany on the possible elimination of varicella, clinical effectiveness (measured as percentage of preventable varicella cases prevented), possibility of age-shifts, and economic outcomes. METHODS: Using an established, age-structured, decision-analytic model named EVITA (Economic Varicella Vaccination Tool for Analysis), we analyze the impact of vaccinating children aged 15 months against varicella-zoster-virus. Main assumptions are: efficacy 86%, costs discounted by 5%, analytic time horizon 30 yrs. Coverage levels are varied from 0% to 100%. RESULTS: For coverage levels above 75%, varicella can be eliminated within 26.5 years (at 75%), 18 years (at 85%) and 14.5 years (at 100%). At coverage levels below 30% clinical effectiveness is smaller than the respective coverage levels, from 40% to 70% clinical effectiveness is higher than coverage showing the strong effect of herd immunity. Above 70% clinical effectiveness remains nearly constant due to the elimination. Because vaccination is very effective in reducing the number of cases in young children, the relative proportion of varicella cases of adolescents and adults increases. However, the total number of cases declines in all age groups for coverage levels above 50%, i.e. no age-shift occurs. Costs rise linear with coverage, savings rise even steeper until 70% coverage and remain constant for higher coverage levels. Therefore, net savings are greatest at coverage levels of about 70%. Benefit-cost-ratios rise up to coverage levels of 70% and fall for coverage higher than 80%. All benefit-cost-ratios are above 1 showing that net savings occur from both perspectives the payers' and the societal. CONCLUSIONS: Epidemiological considerations favor coverage levels of more than 75% to eliminate varicella and to ensure that no age-shift occurs. From